The BMP-9/BMP-10/ALK1 pathway is a promising target for anti-angiogenic cancer therapy and with dalantercept (previously known as ACE-041) a new drug is now being tested, displaying promising antitumor activity in patients with advanced refractory cancer of diverse origins including liver [92], and multiple phase II studies will follow soon. This evidence concerns the gene ACVRL1 and cancer.